Nuvectis Pharma, Inc.
NVCT
$6.49
-$0.38-5.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.79% | 14.66% | -50.45% | 6.21% | -6.16% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.54% | 19.89% | -1.55% | -8.16% | -2.62% |
| Change in Net Operating Assets | 688.57% | -107.95% | 347.80% | 304.11% | 109.84% |
| Cash from Operations | 19.33% | -69.33% | -2.54% | 20.40% | 30.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.34% | 324.94% | 162.31% | -12.74% | -64.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 75.41% | -942.74% | -148.00% | 9.09% | 64.05% |
| Cash from Financing | -98.09% | 304.94% | 162.80% | -12.86% | -64.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.10% | 730.72% | 244.03% | 29.75% | -498.82% |